Board Members

After graduating from the National Defense Academy of Japan, Dr. Takahiro Suzuki joined the Japan Air Self-Defense Force as an Air Chief Marshal and resigned in 2003. After earning a PhD in genomic science in 2009, he engaged in germline and cancer research based on transcriptomics and epigenetics at RIKEN. 2019, he also served as a visiting associate professor at Yokohama City University Graduate School. 2022, he joined Whiz Partners, Inc. In 2023, he served as Business Development Manager of ARCALIS, Inc. co-head, Business Development Manager of Passport Technologies Japan, and a board member of Ascella Biosystems, Inc. At the same time, he also serves as Visiting Principal Researcher at RIKEN, Visiting Associate Professor at Yokohama City University, and Part-time Lecturer at Juntendo University.

After working for NAMCO LIMITED and KYOCERA Communication Systems Co., Ltd. , he was one of the founding members of Omron Entertainment Co., Ltd., where he was involved in sales activities in various departments before becoming division manager and secretary to the chairman. He then served as Deputy General Manager of the Digital Marketing Business Department at SEGA Games Co., Ltd., where he was responsible for budget planning, numerical value management, and promoting internal communication. In March 2021, he assumed the position of President and Representative Director of AXEL MARK, INC., where he implemented profit structure reforms and used his sales skills to conduct top sales, contributing to business growth.

After earning a PhD in genomic science, Dr. Yuki Hasegawa joined the Center for Genomic Sciences in RIKEN as a researcher in 2007 and worked on projects of gene transcription regulatory networks of various cells including iPS cells. After working as a deputy team leader in the Research Center for Life Science Technology Platforms in RIKEN, she joined Asahi Kasei Corporation in 2014 and gained experience in project initiation and other activities within the regenerative medicine research team. In 2016, she joined Whiz Partners, and she has been Head of Healthcare Investment since 2021. In 2023, she was appointed as a Vice Chairperson and General Manager of Business Development of ARCALIS. Dr. Hasegawa also holds concurrent positions as an outside director at ActualEyes Inc. and NANO MRNA Co., Ltd.